ArticleFrontiers in medicine2026
Huoxue Jiegu compound capsule accelerates tibial fracture healing via angiogenesis-driven repair mechanisms.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fracture healing is a complex regenerative process requiring coordinated interactions among vascular, skeletal, and neural systems. Angiogenesis is a critical rate-limiting step that regulates oxygen delivery, inflammatory resolution, and osteogenic cell recruitment within the fracture microenvironment. Huoxue Jiegu Compound Capsule (HXJGCC), a traditional Chinese medicine formulation, has demonstrated clinical efficacy in fracture management; however, its molecular mechanisms underlying fracture repair remain insufficiently elucidated. Methods: An integrative strategy combining network pharmacology, molecular docking, 100-ns molecular dynamics simulations, and Results: A total of 209 candidate active compounds and 185 overlapping targets were identified. Network analysis revealed key hub targets, including AKT1, STAT3, IL6, BCL2, EGFR, and JUN, which were significantly enriched in angiogenesis-related signaling pathways, particularly HIF-1, PI3K-Akt, Relaxin, TNF, and FoxO pathways. Molecular docking and molecular dynamics simulations demonstrated stable interactions between core compounds and target proteins, supporting a multi-component and multi-target mechanism. In vivo experiments showed that HXJGCC significantly increased vascular density and improved vascular architecture in the fracture region. qRT-PCR analysis further confirmed significant upregulation of angiogenesis-associated genes (AKT1, STAT3, IL6, and EGFR), indicating activation of pro-angiogenic regulatory networks. Conclusion: HXJGCC accelerates tibial fracture healing primarily by enhancing angiogenesis and improving the local microvascular microenvironment. Mechanistically, activation of HIF-1/PI3K-Akt-related signaling pathways may coordinate inflammatory responses, vascular remodeling, and downstream osteogenic processes. These findings support the establishment of an angiogenesis-driven repair framework, potentially integrating neuro-vascular-bone interactions, and provide mechanistic insights into the multi-target therapeutic effects of HXJGCC, highlighting angiogenesis-centered regulation as a promising strategy for promoting bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.